Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts
BofA Securities downgraded Editas Medicine Inc (NASDAQ:EDIT), citing few value-driving catalysts in the near term.
In its third-quarter earnings release, Editas Medicine said it engaged an investment bank to lead the process of partnering or out-licensing reni-cel (renizgamglogene autogedtemcel, previously EDIT-301).
The company is developing reni-cel for sickle cell disease and transfusion-dependent Beta Thalassemia.
The company is on track to share additional clinical and patient-reported outcomes data from 28 patients in the RUBY trial for sickle cell disease at the American Society of Hematology Annual Meeting in December.
The company has completed enrollment of the adult cohort of the EdiTHAL trial for thalassemia and continues patient dosing.
The analyst notes that Editas …
Full story available on Benzinga.com